Table 1.
Characteristics of the included randomized controlled trials.
| Studies | Sample size (T/C) | Patients enrolled condition | Diagnosis standard | Treatment group | Control group | Course of treatment (d) | Outcomes |
|---|---|---|---|---|---|---|---|
| Fu et al. [9] | 37/36 | MOCP | 6th Edition | TouxieQuwen prescription (2 dose/d) + Control group | Arbidol (0.2 g, tid) and ambroxol (30 mg, tid) | 15 | 1/2/5/6/7/8 |
| Yang et al. [10] | 26/23 | MOCP | 3/4/5th Edition | Reyanning mixture (10–20 ml, bid-q6h) + Control group | Lopinavir-ritonavir (400–100 mg, bid) or recombinant human interferon α1b for injection (5 million U, bid) or ribavirin (0.5 g, bid) or arbidol (0.2 g, tid) | 7 | 2/3/4/6/8 |
| Qu et al. [11] | 40/30 | MICP and MOCP | 4/5th Edition | Shufengjiedu capsule (2.08 g, tid) + Control group | Arbidol (0.2 g, tid) | 10 | 2/3 |
| Ding et al. [12] | 51/49 | T:MICP:10; MOCP:36; SCP and CCP: 5; C:MICP:11; MOCP:34; SCP and CCP: 4 | 5th Edition | Qingfeitouxiefuzheng prescription (1 dose/d) + Control group | Recombinant human interferon α1b for injection (5 million U, bid) or ribavirin (0.5 g, bid) | 10 | 2/4/8/9 |
| Xiao et al. [13] | 100/100 | MICP | 5th Edition | Shufengjiedu capsule (2.08 g, tid) + Control group | Arbidol (0.2 g, tid) | 14 | 1/2/4/5/7 |
| Huang et al. [14] | 52/14 | T:MOCP:44; SCP:9; C:MOCP:12; SCP:3 | 7th Edition | Feiyanyihao prescription or feiyanerhao prescription (1 dose/d) + Control group | Lopinavir-ritonavir or recombinant human interferon α1b or ribavirin or arbidol (regular recommended dosing) | 10 | 2/3/4/5/6/8/9 |
| Duan et al. [15] | 82/41 | MICP | 5th Edition | Jinhuaqinggan granule (10 g, tid) + Control group | Lopinavir-ritonavir (400–100 mg, bid) or recombinant human interferon α1b (5 million U, bid) or ribavirin (1.2 g, tid) | 5 | 2 |
Abbreviation: T: treatment group; C: control group; d: day; mild case patients (MICP); moderate case patients (MOCP); severe case patients (SCP); critical case patients (CCP); 3/4/5/6/7th Edition: “Diagnosis and Treatment of Pneumonia Infected by 2019-nCoV (trial implementation 3/4/5/67th Edition)” published by the “National Health Commission of the People's Republic of China.”; Outcomes: 1: clinical effective rate; 2: incidence of adverse reactions; 3: viral nucleic acid negative conversion rate; 4: remission rate of pulmonary inflammation (chest CT); 5: white blood cell count (WBC); 6: lymphocyte count (LYM); 7: lymphocyte ratio (LYM%); 8: C-reactive protein (CRP); 9: interleukin 6 (IL-6).